Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Offin

Showing results (31-40 of 88) with videos related to

Pageof 9
Sort By:
JCO Precision Oncology|September 14, 2020
Genomic Characterization of <i>ERBB2</i>-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab EmtansineSebastian Mondaca, Pedram Razavi, Chongrui Xu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2022
Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trialMario Ghosn, Waseem Cheema, Amy Zhu, et al.
International Journal of Radiation Oncology, Biology, Physics|February 14, 2022
Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung CancerNarek Shaverdian, Annemarie F Shepherd, Xingzhe Li, et al.
Annals of Surgical Oncology|July 30, 2025
Clinicopathologic Characteristics and Clinical Outcomes of Patients with Testicular MesotheliomaPrashasti Agrawal, Fady Baky, Judy Sarungbam, et al.
JCO Precision Oncology|June 4, 2019
Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung CancerKen Suzawa, Michael Offin, Adam J Schoenfeld, et al.
Translational Lung Cancer Research|September 12, 2022
Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancerJustin M Haseltine, Michael Offin, Jessica R Flynn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 23, 2021
Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumabMaria Thor, Annemarie F Shepherd, Isabel Preeshagul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
JAMA Network Open|January 5, 2023
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and DurvalumabEmily S Lebow, Annemarie Shepherd, Jordan E Eichholz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 11, 2024
Response letter to "Stereotactic body radiation therapy for pleural mesothelioma: Which goal, which patients"Jacob Y Shin, Michael Offin, Charles B Simone, et al.
Pageof 9

Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
JCO Precision Oncology|September 14, 2020
Genomic Characterization of <i>ERBB2</i>-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab EmtansineSebastian Mondaca, Pedram Razavi, Chongrui Xu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2022
Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trialMario Ghosn, Waseem Cheema, Amy Zhu, et al.
International Journal of Radiation Oncology, Biology, Physics|February 14, 2022
Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung CancerNarek Shaverdian, Annemarie F Shepherd, Xingzhe Li, et al.
Annals of Surgical Oncology|July 30, 2025
Clinicopathologic Characteristics and Clinical Outcomes of Patients with Testicular MesotheliomaPrashasti Agrawal, Fady Baky, Judy Sarungbam, et al.
JCO Precision Oncology|June 4, 2019
Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung CancerKen Suzawa, Michael Offin, Adam J Schoenfeld, et al.
Translational Lung Cancer Research|September 12, 2022
Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancerJustin M Haseltine, Michael Offin, Jessica R Flynn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 23, 2021
Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumabMaria Thor, Annemarie F Shepherd, Isabel Preeshagul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
JAMA Network Open|January 5, 2023
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and DurvalumabEmily S Lebow, Annemarie Shepherd, Jordan E Eichholz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 11, 2024
Response letter to "Stereotactic body radiation therapy for pleural mesothelioma: Which goal, which patients"Jacob Y Shin, Michael Offin, Charles B Simone, et al.
Pageof 9